← Back to Search

Caffeine Consumption for Terbinafine Reaction

N/A
Waitlist Available
Led By Shari Lipner, MD, PhD
Research Sponsored by Weill Medical College of Cornell University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 30 min after consuming caffeine, 60 minutes after consuming caffeine

Summary

This trial studies if drinking caffeine while taking terbinafine for nail fungus affects heart rate or blood pressure. Terbinafine can make caffeine stay in the body longer, possibly causing these changes.

Who is the study for?
This trial is for adults over 18 with a nail infection called onychomycosis who are about to begin treatment with terbinafine. It's not open to pregnant or breastfeeding individuals, those unable to consent, or anyone with a history of anxiety or high blood pressure.
What is being tested?
The study aims to see if drinking caffeinated coffee affects heart rate and blood pressure differently than decaffeinated coffee in patients taking the antifungal medication terbinafine.
What are the potential side effects?
Potential side effects may include changes in heart rate and blood pressure due to caffeine consumption while on terbinafine. Other common side effects from caffeine like jitteriness, insomnia, or digestive issues might also be observed.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 30 min after consuming caffeine, 60 minutes after consuming caffeine
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 30 min after consuming caffeine, 60 minutes after consuming caffeine for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Blood Pressure
Change in Heart Rate

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Caffeinated GroupActive Control1 Intervention
Caffeinated coffee, 1 cup, 8 oz water setting, 95 mg caffeine
Group II: Decaffeinated GroupPlacebo Group1 Intervention
Decaffeinated coffee, 1 cup, 8 oz water setting

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Terbinafine reactions, particularly when considering interactions with caffeine, involve managing cardiovascular symptoms such as changes in blood pressure or heart rate. Beta-blockers can be used to mitigate increased heart rate and hypertension by blocking the effects of adrenaline on the heart. Calcium channel blockers help relax and widen blood vessels, reducing blood pressure. These treatments are crucial for Terbinafine reaction patients because they help manage potentially dangerous cardiovascular side effects, ensuring patient safety and improving overall treatment outcomes.
Developmental exposure to terbutaline and chlorpyrifos, separately or sequentially, elicits presynaptic serotonergic hyperactivity in juvenile and adolescent rats.Quantitative design of optimal analgesic combination of acetaminophen, caffeine, and butalbital.Grapefruit juice-terfenadine single-dose interaction: magnitude, mechanism, and relevance.

Find a Location

Who is running the clinical trial?

Weill Medical College of Cornell UniversityLead Sponsor
1,083 Previous Clinical Trials
1,138,747 Total Patients Enrolled
Shari Lipner, MD, PhDPrincipal InvestigatorWeill Medical College of Cornell University
4 Previous Clinical Trials
51 Total Patients Enrolled

Media Library

Caffeinated Group Clinical Trial Eligibility Overview. Trial Name: NCT05667246 — N/A
Terbinafine Reaction Research Study Groups: Caffeinated Group, Decaffeinated Group
Terbinafine Reaction Clinical Trial 2023: Caffeinated Group Highlights & Side Effects. Trial Name: NCT05667246 — N/A
Caffeinated Group 2023 Treatment Timeline for Medical Study. Trial Name: NCT05667246 — N/A
~35 spots leftby Nov 2025